Advanco and Syntegon have announced a strategic partnership, marking a significant step towards helping to eradicate the growing problem of counterfeit drugs. The counterfeit drug market is estimated to exceed $75Bn and is once again in the spotlight as the world searches for a COVID-19 vaccine. Approximately 10% of pharma products worldwide are estimated to be counterfeit, resulting in up to one million deaths each year.
The one-stop shop serialisation technology resulting from the partnership means that drugs can be tracked at every stage of the supply chain – from the production line to the pharmacy and right through to the patient – helping prove authenticity and help prevent counterfeit activity.
The partnership combines the strength of advanco’s leading site manager system (known as ARC), which handles the serialisation and aggregation processes with Syntegon’s high-end machines for packaging pharmaceutical products and drugs.
The development will bring tremendous value to pharmaceutical companies by significantly lowering the total overall cost and preventing a lock-in effect, allowing vendors to choose different machines from different suppliers, if they choose to do so.
The overall result of the partnership will mark important steps in moving the serialization supply chain from rigid to a much more agile model, encouraging industry openness.
Rami Cassis, CEO and Founder of Parabellum Investments, which acquired advanco in 2020, said: “Regulatory compliance for serialisation is increasingly becoming a focus area for pharmaceutical manufacturers and supply chain partners across the world, positioning firms such as advanco at the very heart of the ongoing evolution of the entire pharma industry.
“It is this exciting proposition that made advanco the perfect fit for Parabellum Investments’ portfolio of firms. We are looking forward to taking the next step with the company as it continues to develop new products and services for the benefit of us all.”
Alf Goebel, CEO of advanco, said: “With most developed and developing economies having either already laid out the regulatory road map for serialisation, or in the process of doing so, cost and time savings will be increasingly important for the pharmaceutical industry, especially due to COVID-19.
“Never has it been so important for product serialisation services to work together to minimize costs for pharmaceutical companies. The advent of the virus will most certainly accelerate the implementation of agile supply chain regulation – this will require a strong industry-standard open interface and interoperability.”